20 March 2017 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of:

• Crizotinib (Xalkori)
  
• Everolimus (Afinitor)
  
• Follitropin delta (Rekovelle)
  
• Obeticholic acid (Ocaliva)
  
• Ceftaroline fosamil acetate monohydrate (Zinforo)
  

Read TC agenda [French]